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SUMMARY
The ILAE Task Force on Classification presents a road map for the development of an
updated, relevant classification of the epilepsies. Our objective is to explain the pro-
cess to date and the plan moving forward as well as to invite further discussion about
the newly proposed terms and concepts. Here, we present our response to feedback
about the 2010 Organization of the Epilepsies and clarify the reintroduction of the
word “classification” to map out a framework for epilepsy diagnosis. We introduce
some new concepts and suggest four diagnostic levels: seizure type, epilepsy category,
epilepsy syndrome, and epilepsy with (specific) etiology to denote specific levels of
diagnosis. We expand the etiological categories to six, focusing on those with treat-
ment implications. Finally, we discuss the changes in terminology originally suggested
and modifications in response to comments from the epilepsy community. We wel-
come feedback and discussion from the global epilepsy community, particularly for the
new suggested terms, so that we can cement a classification that both reflects current
thinking and scientific understanding and provides a dynamic, evolving framework.
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SPECIAL REPORT
The purpose of this article in Epilepsia Open is to update
the community on the work being done by the Task Force
on the Classification of the Epilepsies and to solicit
comments and criticism from readers. Please send your
comments to the ILAE website, http://www.ilae.org/Visi-
tors/Centre/Class-Roadmap.cfm, where all comments are
posted.—The president of the ILAE and the editors in chief
of Epilepsia Open, the new open access journal of the
ILAE.
Classification in epilepsy is primarily for clinical pur-
poses. It influences every clinical consultation, yet its
impact stretches far beyond the clinical domain to clinical
and basic epilepsy research and to the development of
novel therapies. The need for an updated classification of
the epilepsies that reflects current clinical practice has
been recognized for many years because many clinicians
still use the 1989 classification of epilepsies and epilepsy
syndromes.1 With the advent of significant advances in
understanding the neurobiology of seizures and epileptic
diseases, there have been major paradigm shifts in the
concepts underpinning classification. If not updated to
mirror current understanding, the classification will
become irrelevant to clinical practice rather than the pre-
eminent tool for communication in the clinical and
research domains.
The aim of this paper is to describe the process involved
in developing an updated classification, to map out the way
forward, and to invite further thoughts from the epilepsy
community regarding the new suggested concepts and
terms. In addition to this task force focusing on the overall
framework for classification, a second seizure task force is
developing a new structure and lexicon for seizures. We will
ask for comments online regarding the proposals in this
paper and arrange discussion pieces in Epilepsia and educa-
tional settings to further refine the classification.
When is a Classification of the
Epilepsies Accepted and Ready
for Implementation?
The classification of the epilepsies is the mandate of the
ILAE Commission for Classification and Terminology. The
work of many commissions over the last 25 years has driven
thinking forward since the last formal classification in
1989.1 The process for the adoption of an official classifica-
tion of the epilepsies has been somewhat unclear, with com-
mission publications often using the term “proposal” or
“recommendation.” This has meant that members of the epi-
lepsy community have been unsure when they should adopt
a new classification into their daily practice, teaching,
research, and overall lexicon.
Classification is inherently dynamic and will never be set
in stone. In an ideal world, a classification should have a
solid scientific basis. Where there are gaps in knowledge, a
classification is formulated on well-accepted concepts
based on robust scientific evidence. Where our classifica-
tion framework proves incompatible with new findings, we
need flexibility to modify or essentially reconstruct the
framework in light of new insights into this complex group
of diseases. Importantly, however, concepts today consid-
ered as innovative may one day be regarded as outdated
and, in some instances, even proven incorrect. We also rec-
ognize that it is challenging to change practice in terms of
the use of novel nomenclature. We are comfortable using
words that we have employed for many years and have a
natural reluctance to change.
Procedure for Ilae Position
Papers
The ILAE has recently developed a policy for League
position papers.2 Such papers address topics that provide a
common language or definitions for the international epi-
lepsy community, and the classification of the epilepsies
clearly falls within this remit. The Commission for Classifi-
cation and Terminology 2009–2013 followed the policy and
submitted a proposal to refine the 2010 Organization of the
Epilepsies3 largely in response to the feedback received
over the intervening 3 years. After intense review, a docu-
ment was submitted to Epilepsia and posted online (Data
S1). Comments from the global community were invited.
There was a vigorous response, with more than 120 pages of
commentary, and the journal received six reviews. It was
clear that there was a lack of clarity about a number of
issues.
The next stage in the process was the assignment of a new
task force, with the membership determined by the ILAE
executive, comprising members from the previous commis-
sion and the current 2013–2017 commission, together with
members of the executive committee, an Epilepsia editor,
and a few additional invited participants. The task force
met and believes that a road map should be presented outlin-
ing the way forward. The road map should discuss key con-
cepts rather than present a definitive classification because
presenting a classification requires further deliberation and
discussion. Presenting a road map is the purpose of this
paper.
Key Points
• A road map for the development of a revised classifi-
cation of the epilepsies is presented.
• Your comments are invited online; due by 30th August
2016.
• This paper presents a framework for overall epilepsy
classification and is complementary to the revision of
the classification of seizure types currently underway.
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Return to Epilepsy
Classification
The Berg et al.3 report suggested that the term “organiza-
tion of the epilepsies” be used, rather than “classification of
the epilepsies,” to emphasize that the fundamental basis of
the epilepsies is not well understood and cannot be scientifi-
cally classified, in contrast to many areas of biology. This
approach was also designed to promote flexibility in classi-
fication so that one could classify according to any domain
or property (for example, one could classify by myoclonic
seizures, electroencephalogram [EEG] trait, or a host of
other features).4
There was dissatisfaction with, and misunderstanding of,
the term “organization.” The argument has subsequently
been made that, in many areas of medicine, the term “classi-
fication” is employed for disorders based on clinical fea-
tures and without the benefit of a fundamental scientific
understanding. For this reason, the word “classification”
was again brought into favor because it is commonly
employed in clinical practice and clinicians understand that
it provides a framework for diagnosis without being the
final definitive scientific answer. The flexibility underpin-
ning the concept of an organization can still be applied to
the classification and is strongly encouraged. Therefore, a
decision was made to retain the word “classification” to
describe the epilepsies.
Proposal for a Framework for
Epilepsy Classification and
Diagnosis
An overarching framework for classification of the
epilepsies has been developed (Fig. 1). This is designed to
allow diagnosis at multiple levels depending on the infor-
mation and resources available. In the first instance, clini-
cians have to determine whether a paroxysmal event is an
epileptic seizure. Once they have established clinically (or
Figure 1.
Framework for epilepsy classification. The etiological framework can also be used for acute seizures. The term “genetic” refers to the eti-
ology in an individual if there is an epilepsy syndrome that is known to be primarily genetic based on evidence from family and twin studies.
Although the underlying gene may be identified for some individuals, in most cases, the underlying genetic mutation will not be known.
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with support from video, EEG studies, or both) that a patient
is having epileptic seizures, they can make a level 1 diagno-
sis of the patient’s seizure types. A revised classification of
seizure types has been recently developed for further discus-
sion by the epilepsy community.5 In some settings, clini-
cians may not have the resources to take the diagnosis
further, and then classification according to seizure type
may be the maximum level of diagnosis possible. In other
cases, clinicians may simply have too little available infor-
mation to be able to make a higher-level diagnosis, such as
when a patient has had only a single event.
Often, however, a diagnosis regarding the type of epi-
lepsy can be made (level 2: epilepsy classified by seizure
type), and clinicians should strive to make a diagnosis at this
level whenever possible. For many years we have used the
concept of focal and generalized epilepsies in daily practice.
In the 2010 commission publication, it was suggested that
the terms “focal” and “generalized” be reserved for seizure
types rather than for epilepsies per se.3 Following our own
experience and considerable feedback regarding the utility
of the terms “focal epilepsies” and “generalized epilepsies”
in clinical practice, we reinstated these terms with the caveat
that generalized and focal epilepsies do not provide a
dichotomous classification into which all epilepsies can be
squeezed.4 We have therefore added the categories of “gen-
eralized and focal epilepsy” and “unknown if generalized or
focal epilepsy” (Fig. 1).
At the next level (level 3), we aim to make an epilepsy
syndrome diagnosis in our patients. Epilepsy syndromes
are determined by a distinctive clinical pattern and EEG
features. They may have associated imaging, etiological,
prognostic, and treatment implications. Well-recognized
examples include childhood absence epilepsy, juvenile
myoclonic epilepsy, and benign epilepsy with centrotem-
poral spikes.3 The recently released educational ILAE
website, epilepsydiagnosis.org, provides an excellent
resource to aid in understanding the parameters for diag-
nosis, to review videos of seizure types, and to assess the
EEG features of many established syndromes, and it can
be used as a teaching tool around the world by the epi-
lepsy community.
Although Fig. 1 highlights the critical issue of consider-
ing etiology at all levels of epilepsy diagnosis (right-hand
vertical bar), the fourth level of diagnosis establishes that
the primary etiology and epilepsy diagnosis have been
determined. The task force had some debate as to the pre-
ferred term for this level of diagnosis, and suggestions
included “epilepsy with etiology,” “epilepsy with specific
etiology,” and “epilepsy with known etiology.” We wel-
come views regarding this terminology and alternative sug-
gestions. This level of diagnosis opens the gateway to a
precision-medicine approach that reflects current scientific
efforts. Our ability to make an etiological diagnosis is
rapidly increasing with the revolution in genetics and other
fields such as neuroimaging. This means that the definitive
etiology is known, although factors influencing phenotypic
variability are usually not yet understood, such as modifier
genes or the influence of environmental factors. Many new
etiological diagnoses are emerging such as CHD2
encephalopathy, KCNQ2 encephalopathy, and STXBP1
encephalopathy, to name a few.6–9 One of the best-known
examples is an individual with Dravet syndrome, who has a
knownmutation of the sodium channel gene SCN1A.10
In some instances, the epilepsy syndrome may not be
known even though the etiology is established and a level 4
classification can be made. Importantly, an epilepsy syn-
drome does not have a one-to-one correlation with an etio-
logical diagnosis and serves a different purpose, such as
guiding management. For example, SCN1A mutations are
also seen in the milder familial epilepsy syndrome of
GEFS+ (genetic epilepsy with febrile seizures plus). The
GEFS+ spectrum includes the phenotype of febrile seizures
plus, where medication is often not necessary in contradis-
tinction to a patient with Dravet syndrome and an SCN1A
mutation.11,12 Another example is the metabolic condition
of glucose transporter 1 deficiency, for which the ketogenic
diet is the usual therapeutic approach. This can be regarded
as an etiology that causes epilepsy syndromes as diverse as
juvenile absence epilepsy and epilepsy with myoclonic-
atonic seizures in addition to the well-known GLUT1
encephalopathy.13–15 Thus, one genetic cause may be asso-
ciated with several epilepsy syndromes. By making an epi-
lepsy syndrome or an etiological diagnosis, a targeted
therapeutic approach may be possible now or in the future.
An excellent example of precision medicine using the
paradigm of an etiological diagnosis is the finding of a de
novo mutation of the potassium channel gene KCNT1 in up
to 50% of children with the syndrome of epilepsy of infancy
with migrating focal seizures.16 These mutations are associ-
ated with a gain of function of the mutant ion channel.16
This gain of function can be reversed in vitro by an “old”
drug, quinidine, which targets the KCNT1 potassium chan-
nel.17 Quinidine is both an antiarrhythmic agent and anti-
malarial treatment. Open-label trials of quinidine in three
children with KCNT1 mutations and devastating epilepsies
provide the first glimmer of hope for precision medicine,
with improvement in seizure frequency observed in the two
children whose mutations showed the greatest gain of func-
tion in vitro and were associated with the most severe phe-
notype, epilepsy of infancy with migrating focal
seizures.18,19 Although promising, randomized double-
blind placebo-controlled trials are necessary to prove
unequivocal efficacy as a precision medicine.
At all levels of diagnosis, we should consider more
broadly the etiology of the patient’s epilepsy. In some
patients, the etiology will not be known. In others, more
than one known etiology will apply. A range of etiological
groups has been recognized, with emphasis on those that
have implications for treatment. This has been expanded to
include six groups, with room for further expansion as
Epilepsia Open, 1(1):37–44, 2016
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knowledge evolves. The groups are genetic, structural,
metabolic, immune, infectious, and unknown (Fig. 1). In
many instances, multiple etiologies apply and can be used
because they are not meant to be mutually exclusive groups.
For example, tuberous sclerosis complex has both a genetic
and a structural etiology. Both etiological groups provide
support for different, relatively diverse treatment paths:
tuberectomy20 and mammalian target of rapamycin
(mTOR) inhibitors.21
Similarly, patients may have a range of comorbidities
associated with any level of the diagnostic framework
(Fig. 1, left-hand vertical oval). Although long known, a
recent increase in awareness of comorbidities by the epi-
lepsy community means that learning, psychological, and
behavioral features are identified and appropriately man-
aged. In addition, the description of specific comorbidities
with known etiologies allows earlier recognition, diagnosis,
and treatment. For example, girls with PCDH19 mutations
are at risk of severe behavioral and autistic features that
may be far more challenging in terms of management than
are seizures in adolescents and adult women.22
Road Map
The approach planned is to engage the epilepsy commu-
nity in further discussion about the more controversial con-
cepts. This will take place through educational forums in
epilepsy conferences, commentaries and online polls in
Epilepsia Open, and online discussions through the ILAE
website. Commentaries will focus on the major points of
debate. Some examples are provided to stimulate further
discussion.
The term “genetic”
The term “genetic”was also the subject of intense debate.
Although most agree that the term “idiopathic” is outdated
and that many facets of medicine no longer use it, epilepsy
clinicians are comfortable with its use. There was consider-
able misunderstanding of the suggested replacement term
“genetic” because many thought that this meant that the
underlying genetic mutation was known or inherited.
“Genetic” encompasses several concepts, of which one or
all may apply to a specific patient. The most straightforward
is where the causative genetic mutation is known. Specific
genetic mutations are known in only a small minority of
patients with epilepsy. Increasingly, de novo mutations are
found. This explains the absence of a family history of sei-
zure disorders and often the family’s reluctance to accept
that genes could play an etiological role. This finding
emphasizes the distinction between genetic and inherited,
because “genetic” does not mean “inherited.”
On the other hand, a genetic mutation may be inherited,
but not fully penetrant, so that some individuals carrying the
mutation are unaffected. In other settings, complex inheri-
tance may be present where several genes contribute to risk.
Thus, a mutation of one gene may not be sufficient to result
in epilepsy in an individual.
In most instances, the term “genetic” is used to denote
that twin and family studies provide strong evidence for a
genetic basis.23–25 Here, the genes are usually not known,
and the scientific support is based on clinical genetic
research.
The idiopathic generalized epilepsies map to either
generalized genetic epilepsies or generalized epilepsy of
unknown etiology
For the generalized epilepsies specifically, the broad epi-
lepsy syndrome group of the idiopathic generalized epilep-
sies is well established, with the original term “idiopathic”
essentially meaning genetic.1 This group accounts for a
quarter of all epilepsies.26 The collective name “idiopathic
generalized epilepsies” (IGE) encompasses the syndromes
of childhood absence epilepsy (CAE), juvenile absence
epilepsy (JAE), juvenile myoclonic epilepsy (JME), and
epilepsy with generalized tonic-clonic seizures alone
(EGTCS) as well as some cases that do not fit into one of
these clearly defined syndromes. Strong evidence from
family studies and twin studies shows that genetic factors
(typically not known at present) play a predominant etiolog-
ical role. In individuals in whom the generalized epilepsy
cannot be classified as one of these syndromes or when evi-
dence is lacking for a genetic basis, the epilepsy may be
classified as having an unknown etiology. This means that a
generalized epilepsy can be classified as a generalized
genetic epilepsy when sufficient information is present to
indicate a genetic basis. When there is insufficient informa-
tion, the epilepsy is classified as generalized epilepsy of
unknown etiology. One example is an individual with a clin-
ical diagnosis of a specific generalized epilepsy syndrome,
such as juvenile myoclonic epilepsy, for which there is no
family history of seizures. There is debate as to whether the
JME should be classified as generalized epilepsy of
unknown etiology or as generalized genetic epilepsy based
on evidence of a genetic background in other patients with
the same syndrome. The task force welcomes feedback on
this issue and specifically whether the collective term IGE
should be replaced by the term “generalized genetic epi-
lepsy” (GGE) or the mixed term “generalized epilepsy of
genetic or unknown etiology.”
Unfortunately, the term “genetic” carries significant cul-
tural concerns in some countries and leads to additional
stigma for the person with epilepsy. This is an important
point, and we need to find solutions with education about
the meaning of the word “genetic” in the context of etiology.
Epilepsy has a long history of stigma and inappropriate attri-
bution of causation over the last 5,000 years, and we need
to understand that genetic does not mean inherited and is a
common cause of many human diseases. At this time, in cer-
tain countries the label “genetic” creates major problems in
terms of marriage and stigma for affected individuals. The
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doi: 10.1002/epi4.5
41
RoadMap to Developing a Classification of the Epilepsies
classification exists to assist people with epilepsy rather
than to make life more challenging. So, in these settings, it
is suggested that the clinician may elect to classify the
patient as having generalized epilepsy of unknown etiology
if the collective term IGE were to be replaced by the term
“generalized genetic epilepsy” (GGE) rather than by the
mixed term “generalized epilepsy of genetic or unknown
etiology.”
Developmental and epileptic encephalopathies
“Epileptic encephalopathy” was carefully defined in the
Berg et al.3 report as the notion that the epileptic activity
itself contributes to severe cognitive and behavioral impair-
ments above and beyond what might be expected from the
underlying pathology alone (e.g., cortical malformation).
Global or selective impairments can be seen along a spec-
trum of severity and across all epilepsies and can worsen
over time.3
The term “epileptic encephalopathy” for an overarching
group of epilepsies has appropriately gained widespread
use, particularly with regard to the severe epilepsies of
infancy and childhood.27 This term encompasses many of
the well-recognized syndromes such as West syndrome and
Lennox-Gastaut syndrome but, equally, can be applied to
many more recently recognized disorders such as CDKL5
encephalopathy and CHD2 encephalopathy.6,7,28 It implies
that abundant epileptiform activity interferes with develop-
ment, with cognitive slowing and often regression, and
sometimes has psychiatric and behavioral consequences.
Conversely, an important part of the concept is that amelio-
ration of epileptiform activity has the potential to improve
the developmental consequences of the disorder.29,30 The
epileptiform activity can cause regression in a child with
previously normal development or in one who has always
been delayed and then shows developmental plateauing or
regression. This is a critical issue from a clinical perspective
and one often mirrored in the observations of parents.
However, many, if not most, of these disorders are not
solely associated with developmental or behavioral deterio-
ration due to epileptiform activity. For example, in the rela-
tively common encephalopathy of Dravet syndrome,
developmental slowing or regression occurs between 1 and
2 years of age at a time when epileptiform activity is typi-
cally not yet frequent. This suggests a developmental com-
ponent in addition to an epileptic component, with both
aspects likely occurring secondary to the underlying sodium
channel subunit gene (SCN1A) mutation in >80% of cases.
This observation, pertinent to many of the genetic encepha-
lopathies, suggests that a broadening of the terminology,
when appropriate, to include the word “developmental”
acknowledges that both aspects may be playing a role in the
observed clinical presentation. These concepts are critical
for families and clinicians to understand the disease
process.
When patients manifest features of both delayed develop-
ment and very active epileptiform abnormalities, they
could be considered to have a “developmental epileptic
encephalopathy” to emphasize that both features play a role
in their disease. In many instances, when a genetic mutation
of major effect is identified, the patient may have an etiol-
ogy of a gene name encephalopathy, such as “STXBP1
encephalopathy.”When genes are associated with both sev-
ere and self-limited pharmacoresponsive epilepsies, such as
KCNQ2 or SCN2A, then the term “encephalopathy” can be
used to denote the severe form.8,31,32
It is suggested that, moving forward, we can use
the terms “developmental encephalopathy” and “epileptic
encephalopathy” either independently or together, as in
“developmental epileptic encephalopathy,” selecting which-
ever most aptly describes the patient.
Symptomatic generalized epilepsy often maps to
epileptic encephalopathy
The term “symptomatic generalized epilepsy” has gained
widespread use to denote epilepsy with bilateral network
involvement that is symptomatic of the underlying cause. It
has also been used synonymously with secondary general-
ized epilepsy; both typically are associated with intellectual
disability. These terms have also met with considerable con-
fusion, partly because the words are similar to “secondarily
generalized epilepsy,” which refers to seizures that begin in
one part of the brain and then spread to involved generalized
networks. We propose these terms should no longer be
used. Many patients who would have previously been diag-
nosed with symptomatic generalized epilepsy would now
map to a (developmental) epileptic encephalopathy with
generalized, focal, or generalized and focal epilepsy if there
is evidence of worsening of cognition over time. In some
cases, refractory epilepsy can occur in the setting of intellec-
tual disability without worsening, in which case the patient
would have intellectual disability, rather than an epileptic
encephalopathy, with generalized, focal, or focal and gener-
alized epilepsy, depending on their seizure types.
The term “benign”
There is increasing awareness of the comorbidities that
accompany many, if not most, epilepsies. These range from
subtle learning difficulties to intellectual disability, to psy-
chiatric features such as autism spectrum disorders and
depression, to psychosocial concerns. There has been con-
siderable concern that the term “benign” underestimates
these issues in the milder epilepsy syndromes such as
benign epilepsy with centrotemporal spikes (BECTS) and
childhood absence epilepsy (CAE). Despite the gestalt of a
benign syndrome, BECTS may be associated with transient
or long-lasting cognitive effects33,34 and CAE with signifi-
cant psychosocial consequences such as increased risk of
early pregnancy.35 The Berg et al.3 report suggested new
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terms to distill the elements implied in the term “benign.”
These are “self-limited,” to denote the likely spontaneous
resolution of a syndrome such as BECTS, and “pharmacore-
sponsive,” to show that it is expected that this syndrome will
be controlled with the appropriate antiepileptic drugs.3
Here, we have highlighted critical issues that have eli-
cited much discussion and merited the development of new
concepts or terms, including the introduction of an etiologi-
cal level of diagnosis and the question of the most appropri-
ate term or terms to replace IGE. We now need to consider
whether we should apply these new terms to our epilepsy
practice, and we encourage feedback and thoughts from our
global epilepsy community. It is sometimes helpful to start
to employ new terms in practice to see how they work in the
real world, so it would be helpful to hear of your experience.
With further discussion and careful consideration of feed-
back, we will frame a definitive outline of classification
with the support of the ILAE. We very much look forward
to hearing more from the epilepsy community as we con-
tinue to move classification forward.
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